Search - tctmd.com

Displaying 321 - 340 of 1077

Sort: Relevancy | Date

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

Operators’ Radiation Exposure in the Cath Lab Directly Tied to Patient BMI

Todd Neale

January 04, 2019

News Daily News

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

L.A. McKeown

January 03, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Industry News

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

November 07, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

Shelley Wood

October 31, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

Advertisement

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Operators’ Radiation Exposure in the Cath Lab Directly Tied to Patient BMI

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

TCTMD’s Top 10 Most Popular Stories for December 2018

The Biggest News of 2018: TCTMD’s Top 10

Top News in Endovascular Therapy: 2018

Top News in Policy & Practice: 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

TCTMD’s Top 10 Most Popular Stories for October 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content